Loading…
Sudarshan Pharma Industries (BSE 543828)₹35.84−4.09%Specialty Chemicals
In the Sep 2026 quarter (consolidated), Sudarshan Pharma Industries reported sales of ₹217 Cr, up 28.5% from Sep 2025, and net profit of ₹7.80 Cr, up 101.0% year on year. For the year to Mar 2026, sales were ₹702 Cr and net profit ₹23.05 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 99.14 | 129 | 116 | 161 | 145 | 169 | 168 | 221 | 174 | 217 |
| Expenses | 97.43 | 116 | 108 | 146 | 135 | 160 | 157 | 201 | 159 | 197 |
| Operating Profit | 2.09 | 13.09 | 8.00 | 15.98 | 11.07 | 9.24 | 10.90 | 20.25 | 15.94 | 20.67 |
| OPM % | 2.1% | 10.2% | 6.9% | 9.9% | 7.6% | 5.5% | 6.5% | 9.2% | 9.1% | 9.5% |
| Other Income | 0.99 | −0.86 | 0.52 | −0.82 | 1.22 | 1.87 | 1.53 | 4.14 | 1.23 | 1.94 |
| Interest | 3.93 | 3.68 | 3.98 | 4.38 | 5.94 | 5.92 | 6.26 | 7.50 | 8.18 | 10.33 |
| Depreciation | 0.66 | 0.66 | 0.62 | 0.82 | 0.87 | 0.89 | 0.90 | 1.08 | 1.40 | 1.35 |
| Profit before tax | −1.54 | 7.82 | 3.84 | 9.88 | 5.40 | 4.22 | 5.19 | 15.69 | 7.49 | 10.79 |
| Tax % | −22.0% | 24.9% | 24.9% | 25.0% | 26.8% | 8.5% | 20.1% | 27.4% | 25.3% | 27.9% |
| Exceptional items | 0.00 | −0.99 | 0.00 | −0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | −1.22 | 5.89 | 2.89 | 7.43 | 3.97 | 3.88 | 4.16 | 11.42 | 5.63 | 7.80 |
| EPS (Rs) | −0.06 | 0.25 | 0.13 | 0.32 | 0.18 | 0.18 | 0.19 | 0.46 | 0.24 | 0.33 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 148 | 193 | 356 | 461 | 463 | 504 | 702 | 779 |
| Expenses | 143 | 187 | 347 | 447 | 442 | 466 | 654 | 715 |
| Operating Profit | 5.01 | 7.02 | 11.04 | 15.05 | 23.07 | 40.13 | 51.13 | 67.76 |
| OPM % | 3.2% | 3.7% | 3.1% | 3.2% | 4.9% | 8.0% | 7.0% | 8.7% |
| Other Income | 0.00 | 0.00 | 0.00 | 1.01 | 3.01 | 0.00 | 9.02 | 8.84 |
| Interest | 2.99 | 2.99 | 2.99 | 4.98 | 8.97 | 15.94 | 25.89 | 32.27 |
| Depreciation | 0.00 | 0.99 | 0.99 | 0.99 | 0.99 | 1.99 | 3.99 | 4.73 |
| Profit before tax | 1.99 | 3.99 | 6.99 | 8.99 | 14.99 | 21.99 | 30.95 | 39.16 |
| Tax % | 25.9% | 25.0% | 25.9% | 26.0% | 24.9% | 26.0% | 22.9% | — |
| Exceptional items | 0.00 | 0.00 | −0.06 | −0.17 | 0.00 | −2.06 | 0.00 | 0.00 |
| Net Profit | 1.01 | 3.01 | 5.01 | 7.02 | 11.03 | 16.05 | 23.05 | 29.01 |
| EPS (Rs) | 0.10 | 0.20 | 0.37 | 0.30 | 0.49 | 0.67 | 0.98 | 1.22 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 10.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 9.97 | 9.98 | 9.98 | 23.92 | 23.95 | 23.92 | 23.93 |
| Reserves | 10.04 | 13.06 | 20.07 | 77.33 | 88.28 | 107 | 132 |
| Borrowings | 21.01 | 30.01 | 31.01 | 34.01 | 105 | 171 | 285 |
| Other Liabilities | 17.98 | 46.85 | 77.00 | 96.81 | 66.83 | 99.78 | 201 |
| Total Liabilities | 58.00 | 98.90 | 138 | 232 | 283 | 402 | 642 |
| Fixed Assets | 5.98 | 5.97 | 5.98 | 19.92 | 25.88 | 47.78 | 104 |
| CWIP | 0.00 | 0.00 | 1.01 | 0.00 | 2.01 | 23.03 | 3.01 |
| Investments | 0.00 | 0.00 | 0.00 | 12.04 | 14.06 | 30.08 | 0.00 |
| Other Assets | 53.02 | 92.93 | 131 | 200 | 242 | 302 | 534 |
| Inventories | 17.03 | 24.01 | 47.06 | 75.10 | 86.12 | 140 | 219 |
| Trade receivables | 27.07 | 60.13 | 73.19 | 82.21 | 123 | 160 | 234 |
| Cash & equivalents | 0.99 | 0.99 | 0.00 | 11.97 | 0.00 | 0.99 | 0.99 |
| Total Assets | 58.00 | 98.90 | 138 | 232 | 283 | 402 | 642 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 0.99 | 2.99 | −3.99 | −28.92 | 5.99 | −31.90 | −1.99 |
| Cash from investing activity | −3.01 | −1.01 | −1.01 | −26.06 | −5.01 | −21.06 | −78.26 |
| Cash from financing activity | 0.00 | −1.01 | 4.01 | 66.16 | −12.03 | 53.16 | 79.25 |
| Net cash flow | −1.99 | 0.00 | −0.99 | 10.99 | −11.99 | 0.00 | −0.99 |
| Capex | 4.01 | 1.01 | 1.01 | 14.02 | 2.01 | 1.01 | 69.05 |
| Free cash flow | −3.99 | 0.99 | −5.01 | −43.02 | 1.99 | −53.97 | −50.94 |
| CFO / OP % | 19.9% | 49.9% | −19.1% | −179.0% | 35.9% | −74.1% | 7.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 67 | 115 | 76 | 65 | 97 | 117 | 122 |
| Inventory days | 47 | 50 | 52 | 64 | 75 | 118 | 130 |
| Days payable | 40 | 91 | 80 | 78 | 49 | 76 | 111 |
| Cash conversion cycle | 73 | 73 | 47 | 51 | 123 | 157 | 140 |
| Working capital days | 35 | 29 | 27 | 54 | 62 | 52 | 17 |
| ROCE % | — | 15.1% | 19.1% | 15.1% | 14.1% | 16.1% | 15.1% |
For the Sep 2026 quarter, Sudarshan Pharma Industries reported sales of ₹217 Cr, up 28.5% year on year and net profit of ₹7.80 Cr, up 101.0% year on year. The operating margin was 9.5%.
Sudarshan Pharma Industries' sales for the year to Mar 2026 were ₹702 Cr; over the last twelve months they were ₹779 Cr.
Net profit for the year to Mar 2026 was ₹23.05 Cr, and ₹29.01 Cr over the last twelve months. Earnings per share over the same trailing period were ₹1.22.
Sudarshan Pharma Industries reported borrowings of ₹285 Cr at Mar 2026, against cash and equivalents of ₹0.99 Cr.
Cash from operations was −₹1.99 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹50.94 Cr.